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Abstract
Purpose
Although multiple serum antiretinal autoantibodies (ARAs) have been reported in patients
with paraneoplastic and non-paraneoplastic autoimmune retinopathy ((n)pAIR), not all reti-
nal antigens involved in (n)pAIR are specified. This study aims to serologically identify
patients with presumed (n)pAIR through determination of both known and unknown ARAs
by autoantibody profiling.
Methods
An antigen suspension bead array using 188 different antigens representing 97 ocular pro-
teins was performed to detect ARAs in serum samples of patients with presumed (n)pAIR (n
= 24), uveitis (n = 151) and cataract (n = 21). Logistic regressions were used to estimate the
associations between ocular antigens and diagnosis. Validation of interphotoreceptor matrix
proteoglycan 2 (IMPG2) and recoverin antigens was performed by immunohistochemistry
and immunoblot, respectively.
Results
Samples of patients with presumed (n)pAIR exhibited a broad spectrum of ARAs. We identi-
fied retinal antigens that have already been described previously (e.g. recoverin), but also
identified novel ARA targets. Most ARAs were not specific for (n)pAIR since their presence
was also observed in patients with cataract or uveitis. High titers of autoantibodies directed
against photoreceptor-specific nuclear receptor and retinol-binding protein 3 were more
common in patients with presumed (n)pAIR compared to uveitis (p = 0.015 and p = 0.018,
respectively). The presence of all other ARAs did not significantly differ between groups. In
patients with presumed (n)pAIR, anti-recoverin autoantibodies were the most prevalent
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ARAs. Validation of bead array results by immunohistochemistry (anti-IMPG2) and immuno-
blot (anti-recoverin) showed concordant results in (n)pAIR patients.
Conclusions
Patients with (n)pAIR are characterized by the presence of a broad spectrum of ARAs. The
diagnosis of (n)pAIR cannot be based on the mere presence of serum ARAs, as these are
also commonly present in uveitis as well as in age-related cataract patients.
Introduction
Paraneoplastic and non-paraneoplastic autoimmune retinopathy ((n)pAIR) is a rare blinding
retinal disorder of unknown pathogenesis. It is presumed that antiretinal autoantibodies
(ARAs) are involved in the pathogenesis of (n)pAIR and damage ocular tissue causing poor
visual outcome. Symptoms associated with (n)pAIR are progressive visual loss (most often
bilateral), visual field loss frequently associated with a ring scotoma or loss of the peripheral
field, and decreased amplitudes on electroretinogram (ERG). [1–4]
Paraneoplastic autoimmune retinopathy (pAIR) includes two subgroups: cancer associated
retinopathy (CAR) and melanoma associated retinopathy (MAR). In pAIR the presence of the
same auto-antigens in both retinal tissue and malignant tissue has previously been described
(e.g. recoverin). [5–7] The presence of ARAs however is not conclusive for the diagnosis of (n)
pAIR, since several ARAs were also reported in patients with other ocular disorders and indi-
viduals without ocular disease. [8] Nevertheless, ARAs are considered to support the diagnosis
of (n)pAIR, which is often difficult to confirm by clinical symptoms only.[9]
Multiple serum ARAs have regularly been reported in affected patients (Table 1), although
not all retinal autoantibodies involved in the pathogenesis of (n)pAIR are known and informa-
tion regarding their exact pathological roles is lacking. [10] Further, a gold standard for the
determination of ARAs is missing. [11–13] The optimal approach for the determination and
specification of ARAs is currently unknown. Different techniques, including indirect immu-
nofluorescence, western blot and enzyme-linked immunosorbent assay (ELISA), have been
used for the detection of ARAs; however, results and conclusions differ and cannot be reliably
compared.
Currently, antigen bead arrays are being used to profile autoantibody reactivity in body
fluids.[38] With this technique, very small volumes of body fluids can be tested for IgG reac-
tivity across hundreds of samples towards hundreds of different antigens. This technique
has already successfully been used for the analysis of autoantibodies in serum and cerebro-
spinal fluid. [39–41]
Our study aimed to serologically identify patients with presumed (n)pAIR through deter-
mination of ARAs. For this purpose, we used a bead array-based multiplex assay for autoanti-
body profiling using 188 ocular antigens representing 97 different retinal proteins.
Methods
Sample collection and patient selection
Serum samples were either collected during routine diagnostic analysis for the presence of
anti-recoverin autoantibodies in the Laboratory of Medical Immunology of the Erasmus Uni-
versity Medical Center between April 2013 and August 2015 or were obtained from biobank of
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our department. The study was approved by the local ethical committee from the Erasmus
University Medical Center (Medical Ethics Committee Erasmus MC) and adhered to the
tenets of the Declaration of Helsinki. The ethical committee decided that no informed consent
of patients was required for the use of the remainder of the diagnostic material, as the samples
were anonymized and the patients were not subjected to additional risk or procedures. Sam-
ples which were obtained from the biobank (for which an approval of the ethical committee
was obtained) included signed informed consent from all participants. All whole blood sam-
ples were centrifuged after at least 30’ clotting time at 3,000 rpm for 10 minutes, and serum
was stored at -80˚C.
According to the recently published report on the nomenclature of (n)pAIR, the general
term autoimmune retinopathy (AIR) is recommended to indicate the non-paraneoplastic
autoimmune retinopathy (npAIR) subtype. In our present series we indicate the specific sub-
type(s) of AIR (pAIR, npAIR or (n)pAIR) to prevent any misunderstanding regarding nomen-
clature.[9] The diagnosis of presumed (n)pAIR was made if the patients fulfilled all of the
following inclusion criteria: 1. visual complaints, 2. markedly decreased amplitudes on ERG, 3.
visual field loss, and 4. no alternative explanation for their ocular disorder. In addition,
patients with genetically proven retinitis pigmentosa or a family history of retinitis pigmentosa
were excluded. A total of 17 patients fulfilled the criteria indicated above and were included in
this study. Patients fulfilling the criteria without a malignancy were indicated as presumed
Table 1. Previously described antiretinal autoantibodies in serum of patients with paraneoplastic and non-paraneoplastic autoimmune retinopa-
thy [1, 14, 15].
Antigen Associated with Location in retina Size
(kDa)CAR MAR npAIR
Recoverin [16] x x x Inner segments and nuclei of photoreceptor cells, outer
plexiform layer
23
α—Enolase [17] x x x Inner segments of the cone cells, Mu¨ller cells and
ganglion cell layer
46
Carbonic anhydrase II [18] x x x Ganglion cell layer, inner nuclear layer, outer segments
of photoreceptors
30
Heat shock cognate protein 70 [19] x x x N/A 65
Transducin α [20] (guanine nucleotide-binding protein G(t)
subunit alpha-1)
x x x Outer and inner segments of photoreceptor cells,
cytoplasm of ganglion cells
40
Transducin β [21] (guanine nucleotide-binding protein G(I)/G
(S)/G(T) subunit β-1)
x x Photoreceptor cells, ganglion cell layer 35
Arrestin (S-antigen) [22, 23] x x Photoreceptor cells 48
Interphotoreceptor binding protein [24–26] (retinol binding
protein 3)
x x Outer and inner segments of photoreceptor cells 141
Rhodopsin [27, 28] x x Rod photoreceptor cells 40
Photoreceptor-cell-specific nuclear receptor [29] x Outer nuclear layer 44.7
Mu¨ller-cell-specific antigen [30] x x N/A 35
Transient receptor potential cation channel subfamily M,
member 1 [31–34]
x x x Bipolar cells 182
Tubby-like protein 1 [35] x x Photoreceptor cells 78
Bestrophin-1 [36] x Basal lateral membrane of retinal pigment epithelium 68
Aldolase A and C [15] x x Ganglion cell layer, inner nuclear layer (aldolase C) 39
Glyceraldehyde 3-phosphate dehydrogenase [37] x x x Rod outer segments 30 and
36
Abbreviations: CAR: cancer associated retinopathy, MAR: melanoma associated retinopathy, npAIR: non-paraneoplastic autoimmune retinopathy
doi:10.1371/journal.pone.0167909.t001
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npAIR (N = 9), and patients with a malignancy were indicated as patients with presumed
pAIR (N = 8).
An additional group of presumed pAIR (CAR or MAR) patients (N = 7) in whom ERG or
visual field tests were not performed (choice of the patient or poor general condition), but who
fulfilled all other inclusion criteria, was included separately. An additional required criterion
for these patients comprised the development of a malignancy before or within 3 months after
presentation with ocular problems.
We collected various clinical data of the patients with presumed (n)pAIR, including patient
demographics (age and gender) and ocular characteristics such as complaints of photopsia, com-
plaints of nyctalopia, subjective or objective problems with colour-vision, unilateral or bilateral
visual problems and the presence of a malignancy in the medical history or during follow-up.
Controls consisted of two groups: 21 serum samples from cataract patients without retinal
damage and 151 samples from patients with uveitis of different causes. Patients with age related
cataract were included as controls rather than healthy people, as this disorders does not involve
retina nor exhibits retinal damage, and represents a clinical setting in which the tests might be
employed. Samples of control patients were collected at the department of Ophthalmology of
the Erasmus University Medical Center between February 2009 and April 2015. Patient demo-
graphics (age and gender) and known malignancies of these patients were registered.
Antigen suspension bead array
Autoantibody profiling was performed in all serum samples from patients with presumed (n)
pAIR (n = 24), uveitis (n = 151) and cataract (n = 21). Antigens used for the autoantibody pro-
filing were selected based on potential relevance to ocular diseases according to literature and
previous positive retinal immunohistochemistry staining, resulting in 188 antigens (human
protein fragments) representing 97 unique proteins. The protein fragments were produced
within the Human Protein Atlas and designed to represent unique parts of each target protein.
[42, 43] Protein fragments were 20–150 amino acids long (median 78 aa) and produced in
Escherichia coli, with an affinity tag consisting of six histidines and an albumin binding domain
from streptococcal protein G (His6ABP) (S1 Table). Immobilization onto color-coded mag-
netic beads was conducted as described previously [39]. In short, diluted antigens were cova-
lently coupled to activated carboxy groups on color coded polystyrene beads (MagPlex,
Luminex Corp.) by undirected amine coupling. In addition to the selected protein targets, one
bead identity was used for immobilization of anti-human IgG (positive control), one for
Epstein-Barr virus nuclear antigen 1 (second positive control), one for His6ABP (negative con-
trol, to monitor binding to the affinity tag) and one bead identity went through the coupling
process without addition of antigen (second negative control, to monitor binding to bare
beads). After incubation, the coupled beads were washed and stored in a blocking reagent
before combining all bead identities to create a bead array in suspension. Samples were distrib-
uted across 96-well microtiter plates, together with triplicate aliquots of a sample pool and a
buffer blank in each plate for determination of the intra- and inter-reproducibility. Serum
samples were diluted 1:250 in assay buffer before being mixed with the bead array. Incubation
was performed at room temperature for 2 hours followed by detection of the IgG reactivity by
a fluorophore conjugated anti-human IgG Fab fragment and measured in a FlexMap3D
instrument (Luminex Corp.).
Recoverin immunoblot
For validation purposes, samples that tested positive for anti-recoverin autoantibodies on the
antigen bead array, and all samples from patients with presumed (n)pAIR, were analysed on a
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recoverin specific immunoblot (Euroimmun AG, Lubeck, Germany). Membrane strips coated
with recombinant human recoverin were incubated with a sample buffer for 5 minutes. After
aspiration of the sample buffer, the membrane strips were incubated with diluted serum sam-
ples for 30 minutes on a shaking platform. Subsequently membrane strips were washed three
times, incubated with secondary antibodies (enzyme conjugated anti-human IgG), washed
again for three times and stained with a substrate solution which was capable of promoting an
enzymatic colour reaction. To identify positive reactions, assessment of visible bands was per-
formed relative to the included control. Results from the antigen suspension bead array and
the recoverin specific immunoblot were compared.
Immunohistochemistry of interphotoreceptor matrix proteoglycan 2 on
human retina tissue
Another method for validation was performed with the antigens of interphotoreceptor matrix
proteoglycan 2 (IMPG2). Polyclonal antibodies affinity purified against the IMPG2 antigens
no. 214 and 205 were used as antigens for immunization of rabbits to generate polyclonal anti-
bodies for immunohistochemistry on normal human tissues, in order to determine retina
specificity and cell type expression. The antibodies were applied on tissue microarrays (TMAs)
containing samples from 45 different human tissues, including retina from two individuals.
TMAs from human tissues were generated essentially as previously described.[44] The TMAs
contained 1 mm diameter formalin-fixed and paraffin-embedded tissue cores from 45 differ-
ent histologically normal tissue types, including two samples of human eye: one male 75 years
and one female 54 years. All samples were received from the Department of Pathology, Upp-
sala University Hospital, Sweden, approved by the local Research Ethics Committee (Uppsala,
Sweden, Ups 02–577). Four-micrometer sections were cut from the TMA blocks, mounted on
adhesive slides and baked at 60˚C for 45 min. TMA slides were then deparaffinised in Neo-
Clear1 (Merck Millipore, Darmstadt, Germany), followed by hydration in graded alcohols
and blocking for endogenous peroxidase in 0.3% hydrogen peroxide. For antigen retrieval,
slides were immersed and boiled in Citrate buffer1, pH6 (Lab Vision, Freemont, CA) for 4
min at 125˚C and then allowed to cool to 90˚C. Automated immunohistochemistry was per-
formed essentially as previously described, using an Autostainer 480 instrument1 (Lab
Vision).[44] Affinity purified polyclonal antibodies towards IMPG2 (HPA008779, antigen
number 205, diluted 1:250 and HPA015907, antigen number 214, diluted 1:2500, both Atlas
Antibodies AB) and a dextran polymer visualization system (UltraVision LP HRP polymer1,
Lab Vision) were incubated for 30 min each at room temperature. Slides were developed for
10 min using Diaminobenzidine (Lab Vision) as chromogen. All incubations were followed by
rinse in Wash buffer1 (Lab Vision) for 5 min. The slides were counterstained in Mayers
hematoxylin (Histolab) and cover slipped using Pertex1 (Histolab) as mounting medium.
Digital whole slide high-resolution images were captured with a 20× objective using an Aper-
ioScanScope XT Slide Scanner (Aperio Technologies, Vista, CA).
Data analysis
Continuous variables were summarized using medians and ranges, and categorical variables
were summarized using percentages. Patient demographics were compared between diagnosis
groups using Mann Whitney U tests for continuous data and Fisher’s exact tests for categorical
data. All data from the antigen suspension bead array were represented as ratios (antigen spe-
cific reactivity over patient background (represented by the His6ABP negative control bead)).
A ratio of>2 was considered positive and a ratio of>25 was considered highly positive for the
presence of ARAs. Logistic regressions with correction for age and gender were performed to
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analyse differences between the diagnosis groups ((n)pAIR versus uveitis and (n)pAIR versus
cataract) for both ratio’s. In the logistic regression analyses, confidence intervals of the esti-
mated odds ratios were calculated using a profile likelihood method, and the differences
between groups were tested using a likelihood ratio test. To adjust for the multiple compari-
sons of the different antigens, a Bonferroni correction was used for the P-values of the logistic
regression analyses, so that only P-values 0.0002 were considered statistically significant in
these analyses. Intra- and inter-assay reproducibility was calculated with the coefficient of vari-
ation using the technical replicates within and between plates, based on the pooled serum
samples.
The distribution of age, gender and the most prevalent ARAs (using the cut-off values for
the ratio of 2 and 25) were compared between the subtypes of AIR (pAIR, npAIR) using Mann
Whitney U tests for continuous data and Fisher’s exact tests for categorical data. The number
of different ARAs per patient in highly positive titres were counted and compared between
groups using a linear-by-linear association chi-square test. The association between the num-
ber of ARAs and age was assessed using Spearman’s rank correlation coefficient. All statistical
tests were two-sided and used a significance level of 0.05. The analyses were performed using
SPSS and R. [45]
Results
Patient characteristics
Characteristics of the patients with presumed (n)pAIR (N = 24) are specified in Table 2. The
median age of patients was 67 years, with a range of 27–86 years. The majority of the patients
were female (17/24, 71%). Most patients had bilateral visual complaints (21/24, 88%), and
photopsia, nyctalopia and colour vision problems were noted frequently (12/19, 63%; 11/13,
85%; 9/11, 82%). A malignancy was seen in 15/24 (63%) patients (indicative for pAIR: CAR or
MAR), of whom 8/24 (33%) patients had a malignancy in the past and 7/24 (29%) patients
developed a malignancy during follow-up. The most frequently diagnosed malignancy was a
lung carcinoma (6/15; 40%). A total of 9/24 (38%) patients did not have a malignancy and
were diagnosed with presumed npAIR. Comparison of patient demographics (age and gender)
between groups showed that patients with uveitis were significantly younger than patients
with AIR (p<0.001). Gender did not differ between groups.
Table 2. General characteristics of patients.
Patient characteristics (n)pAIR (N = 24) Uveitis (N = 151) Cataract (N = 21)
Gender (male-female) 7 (29%)–17 (71%) 63 (42%)– 88 (58%)p = 0.271 † 10 (48%)– 11 (52%)p = 0.233 †
Age in years (median; min-max) 67; 27–86 49; 17-86p<0.001 † 69; 48-83p = 0.339 †
Bilateral visual complaints 21/24 (88%)
Complaints of photopsia 12/19 (63%) *
Complaints of nyctalopia 11/13 (85%) *
Colour-vision problems 9/11 (82%) *
Presence of malignancy (pAIR)
• Malignancy in history
• Malignancy during follow-up
15/24 (63%)
• 8/24 (33%)
• 7/24 (29%)
* Data not available for all patients
† p-value of comparison with (n)pAIR patients
Abbreviations: (n)pAIR: non-paraneoplastic and paraneoplastic autoimmune retinopathy
doi:10.1371/journal.pone.0167909.t002
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Antigen suspension bead array: highly positive titres of ARAs (ratio > 25)
Patients with presumed (n)pAIR were characterized by the presence of a wide spectrum of
ARAs (Fig 1 and S1 Fig). There was no specific ARA associated with a majority of patients
with presumed (n)pAIR. In patients with presumed (n)pAIR, anti-recoverin autoantibodies
were the most prevalent ARAs (12.5%). The presence of anti-recoverin autoantibodies was not
fully specific for (n)pAIR, since high titres were also present in sporadic patients with cataract
(4.8%; p = 0.351) or uveitis (1.3%; p = 0.061). Further, no association between the presence of
anti-recoverin autoantibodies and a malignancy was found. High titre autoantibodies to pho-
toreceptor-specific nuclear receptor and retinol-binding protein 3 were more prevalent in
patients with (n)pAIR than in patients with uveitis (p = 0.015 and p = 0.018, respectively; p-val-
ues were not significant after applying correction for multiple testing). Autoantibodies towards
IMPG2 (antigen number 205) were prevalent with highly positive titres in two patient samples
with (n)pAIR (8.3%) and with lower prevalence in uveitis patients (2.0%). The results of the
most prevalent ARAs present in high titres (ratio > 25) in patients with presumed (n)pAIR are
shown in Table 3. The ARAs (in highly positive titres) indicated in Table 3 were only found in
patients with presumed pAIR with the exception of two patients with presumed npAIR (one
patients with npAIR was positive for high titres of antibodies against progressive rod-cone
degeneration protein and one patient for high titres of Cbp/p300-interacting transactivator 1).
The prevalence of high-titre ARAs (from Table 3), age and gender did not significantly differ
between patients with npAIR and pAIR (all p > 0.05).
The number of highly positive ARAs present in individual patients is shown in table 4. A
higher number of different ARAs per patient was most prevalent in patients with presumed
(n)pAIR and least present in patients with cataract. Three or more different ARAs were pres-
ent in 29% of the patients with presumed (n)pAIR, compared to 24% of the patients with uve-
itis and 14% of the patients with cataract. The number of highly positive ARAs did not show
any statistical differences between presumed (n)pAIR and uveitis (p = 0.457) or cataract
(p = 0.385). Furthermore, there was no correlation between the number of ARAs and age
(p = 0.926).
Antigen suspension bead array: positive titres of ARAs (ratio > 2)
The samples of patients with presumed (n)pAIR as well as both control cohorts exhibited a
broad spectrum of positive ARAs (Fig 1 and S1 Fig). None of the ARAs were specific for pre-
sumed (n)pAIR only. Autoantibodies directed against serotonin N-acetyltransferase, cbp/
p300-interacting transactivator 1 and retinitis pigmentosa 1-like 1 protein were more prevalent
in patients with presumed (n)pAIR than in patients with uveitis (p = 0.003, p = 0.017 and
p = 0.020; p-values were not significant after applying correction for multiple testing). When
comparing the serum of patients with presumed (n)pAIR to the serum of patients with cata-
ract, in presumed (n)pAIR autoantibodies directed against sodium/potassium/calcium
exchanger 1 and pigment epithelium-derived factor were more often present (p = 0.037 and
p = 0.030). The presence of most ARAs indicated in Table 3 was predominantly found in
patients with presumed pAIR (CAR or MAR), but (often less frequently) also in patients with
presumed npAIR. The prevalence of low-titre ARAs (from Table 3) was not significantly dif-
ferent between patients with npAIR and pAIR (p> 0.05).
The coefficient of variation based on replicates of the serum pools within and across plates
(indicating the intra- and inter-reproducibility) ranged between 5 and 23% (median = 13%)
for all 188 antigens. ARAs were present in all patients with presumed (n)pAIR and conse-
quently all fulfilled the recent criteria for the diagnosis of (n)pAIR.[9]
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Fig 1. Spectrum of antiretinal autoantibodies in patients suspected of paraneoplastic and non-
paraneoplastic autoimmune retinopathy. Blue: highly positive titer for the presence of antiretinal
antibodies. Dark red: positive titer for the presence of antiretinal antibodies.
doi:10.1371/journal.pone.0167909.g001
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Recoverin immunoblot
Anti-recoverin autoantibodies on immunoblot were positive in 3 out of 24 (12.5%) patients
with (n)pAIR. These positive results were in accordance with the positive high titre results on
the antigen suspension bead array. Occasional discrepancy between the recoverin immunoblot
and the antigen suspension bead array (using a high cut-off value, ratio > 25) was found in the
controls (3 patients positive in antigen suspension bead array while negative on recoverin
immunoblot).
IMPG2 expression in human retina tissue
The antigens towards IMPG2 (antigen number 214 and 205) represent two non-overlapping
domains of IMPG2, located either extracellularly or in the cytoplasm (Fig 2A).[46] Antibodies
directed against antigens 214 and 205, showed staining exclusively in cells in the photoreceptor
layer of the retina. The antibodies targeting the cytoplasmic region of IMPG2 (against antigen
number 205) stained only the inner segment of the photoreceptor layer, while HPA0015907
(antibodies against antigen number 214) stained both inner and outer segment (Fig 2D).
Discussion
Our study shows that patients with (n)pAIR are characterized by the presence of a broad spec-
trum of various ARAs. We identified ARAs that have already been described in previous stud-
ies, such as anti-recoverin autoantibodies, but also identified new retinal targets. Our findings
illustrate that serum ARAs are not only present in patients with (n)pAIR, but also in patients
with cataract and uveitis. Though some ARAs appeared to be specific for (n)pAIR, their preva-
lence and consequently their sensitivity as markers for (n)pAIR were low. This autoantibody
screening using 188 antigen provides insight into the autoimmune repertoire of patients with
(n)pAIR and a base for further validation with independent methods for protein analysis and
independent sample cohorts.
A gold standard for the determination of ARAs is currently lacking.[11] Different tech-
niques are being used, hampering the comparison of results from various laboratories. [47]
Moreover, the mere presence of ARAs does not provide any information on the role of this
specific antibody.
In addition, information on clinical relevance of the specific ARAs and their pathological
titres are lacking. A combination of different ARAs was observed in some cases and therefore
their individual effects on retinal tissue could not be distinguished.
In our study, we performed statistical analyses using different cut-off levels. By using a high
cut-off value, a ratio > 25, false positive results were minimized and retinal targets with a high
Table 4. Number of highly positive antiretinal autoantibodies per patient.
No. of highly positive ARAs (ratio > 25) (n)pAIR (N = 24) Uveitis (N = 151) Cataract (N = 21)
0 37.5% (9/24) 45.7% (69/151) 52.4% (11/21)
1 33.3% (8/24) 29.8% (45/151) 33.3% (7/21)
2 12.5% (3/24) 13.2% (20/151) 4.8% (1/21)
3 12.5% (3/24) 7.9% (12/151) 4.8% (1/21)
4 4.2% (1/24) 2.6% (4/151) 0% (0/21)
5 0% (0/24) 0.6% (1/151) 4.8% (1/21)
Abbreviations: (n)pAIR: non-paraneoplastic and paraneoplastic autoimmune retinopathy, ARAs: antiretinal
antibodies
doi:10.1371/journal.pone.0167909.t004
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specificity for (n)pAIR were found. The low cut-off value, a ratio of>2 (indicating ARAs with
at least twice the reactivity of the negative control), was used for a more sensitive approach,
limiting the exclusion of possibly relevant ARA targets with a lower titre. However, with both
cut-off values, no ARAs were found eligible for diagnostic purposes. Some ARAs were specific
for (n)pAIR, but had low prevalence while others were more frequently identified but lacked
specificity.
In concordance with previous findings, positive results of serum anti-recoverin autoanti-
bodies were not only observed in patients with presumed (n)pAIR, but also in patients with
uveitis and cataract. Furthermore, no association between the presence of autoantibodies
Fig 2. Screening and validation for interphotoreceptor matrix proteoglycan 2. (Left panel, A-D) The path from antigen design and
generation to autoantibody screening in serum and secondly protein expression in retinal tissue. (A) Two antigens representing non-
overlapping regions with either an extracellular or cytoplasmic location of IMPG2 were selected for recombinant protein expression (antigen
214 and 205 respectively, amino acids highlighted in black). (B) Detection of autoantibody reactivity with IMPG2 antigens using the antigen
suspension bead array. Ratios > 25 are displayed per disease group for antigen 214 (left) and 205 (right). (C) The antigens were further used
as antigens for immunization of rabbits to generate polyclonal antibodies. (D) Antibodies HPA015907 and HPA008779, affinity purified
against antigens 214 and 205, were applied for immunohistochemical staining of human retina tissue. Both antibodies specifically showed
cytoplasmic staining of cells in the photoreceptor layer in the retina (D, right). The antibody targeting the CP region of IMPG2 (HPA008779)
stained only the inner segment of the photoreceptor layer, while HPA0015907 stained both inner and outer segment. EC; extracellular, CP;
cytoplasmic, IMPG2; Interphotoreceptor matrix proteoglycan 2. Color annotation for central panel: black; Human Protein Atlas antigens and
antibodies, red; human sample serum and tissue and grey; assay consumables suspension bead array and labelled detection antibodies.
doi:10.1371/journal.pone.0167909.g002
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directed against recoverin and the presence of a malignancy was found. A discrepancy between
the antigen suspension bead array results for anti-recoverin and the anti-recoverin immuno-
blot was found in three control patients (one with cataract and two with uveitis). The differ-
ence in results could be explained by the different techniques used for determination of ARAs
imposing differences in analytical performance. Possibly, the number and/or availability of
recoverin antigenic epitopes differed between the antigen suspension bead array and the
immunoblot technique. The protein fragments we used in this study to screen for autoanti-
body reactivity in serum were designed to represent unique parts of each target protein. The
binding of the autoantibodies towards their target may be influenced by the protein folding of
antigens and may differ in comparison to full-length protein arrays or peptide arrays. Both lin-
ear and conformational epitopes, recognized by some ARAs, might be missed for some pro-
teins, preventing recognition by certain autoantibodies.
The identification of new ARAs in (n)pAIR is in line with findings from previous studies
using Western blot analysis for the determination of ARAs.[11, 48] Although many ARAs
have already been identified, several studies have described so far unknown retinal autoanti-
bodies presumably damaging retinal tissue and causing loss of vision.[14] In our study, we
were able to identify novel ARAs possibly associated with (n)pAIR, e.g. serotonin N-acetyl-
transferase. Serotonin N-acetyltransferase plays a role in melatonin synthesis and is expressed
only in the pineal gland and retina.[49] Autoantibodies directed against serotonin N-acetyl-
transferase have to our knowledge not been described in (n)pAIR so far. Another novel,
although unspecific ARA found in this study is anti-G protein-coupled receptor kinase 7.
Interestingly, it has been suggested previously that G protein-coupled receptor kinases in can-
cer cell lines are functionally associated with recoverin.[50] Moreover, protein IMPG2 was
identified as an ARA and reactivity towards the cytoplasmic protein region (antigen number
205) was associated with (n)pAIR. Autoantibody reactivity towards a second antigen repre-
senting an extracellular region of IMPG2 was in contrast present in serum from uveitis
patients. In short, ARAs targeting IMPG2 were identified using antigen arrays in serum sam-
ples and a retina specific protein expression of IMPG2 identified using immunohistochemistry
in healthy human tissue.
Our present study focused on the autoantibodies prevalent in serum, which reflects sys-
temic production and is probably not influenced by potential (additional) production or accu-
mulation of specific autoantibodies within the eye. Analysis of local, intraocular retinal
autoantibodies might show an entirely different pattern and may differ in clinical importance
compared to retinal autoantibodies found in the peripheral circulation. The importance of
locally produced autoantibodies has already been shown in cerebrospinal fluid for the central
nervous system. In addition, it is unknown which autoantibodies penetrate from the circula-
tion, through the blood retina barrier, into the retina and cause a local inflammation. Further
research addressing the intraocular presence of specific retinal autoantibodies might elucidate
the clinically relevant autoimmune processes directed against the retinal tissue in (n)pAIR.
A gold standard for the definitive diagnosis of (n)pAIR is currently lacking. Also in this
study, the diagnosis of presumed (n)pAIR was based on clinical symptoms. To compensate for
this inaccuracy, we used strict inclusion criteria and selected a uniform cohort of patients with
unexplained visual loss, visual field defects and decreased or absent ERG while other diagnostic
possibilities leading to this configuration of clinical characteristics were (so far as possible)
excluded. The presence of ARAs was found in all our patients with presumed (n)pAIR and
therefore all fulfilled the criteria for the diagnosis of (n)pAIR.[9]
Although the mere presence of ARAs supports the diagnosis of (n)pAIR, it has been stated
that there are no specific ARAs which would be exclusive for (n)pAIR and none of the ARAs
were identified to be of higher diagnostic value than other ARAs.[4, 9, 14] Our results are in
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full agreement with this statement. Proof for the definitive diagnosis of (n)pAIR is still missing
and even the presence of ARAs is not specific for (n)pAIR, which has been illustrated by the
finding of ARAs in control groups and healthy individuals.[8, 51, 52]
In conclusion, our study identified a heterogenous reactivity pattern of ARAs in serum of
patients with (n)pAIR, although the presence of ARAs was not discriminatory between (n)
pAIR, cataract and uveitis and exhibited a low sensitivity. Therefore, the diagnosis of (n)pAIR
cannot be based on the mere presence of serum ARAs and such presence thus warrants careful
interpretation. The determination of ARAs in intraocular fluid might provide more insight
into the pathogenesis of (n)pAIR and might indicate more sensitive and specific diagnostic
tools. Therefore, future research on the prevalence of ARAs in ocular fluid represents an
important next step.
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